Evidence map›Paper›PMID 34711268›Full record

ArticleGenome medicine2021

Novel temporal and spatial patterns of metastatic colonization from breast cancer rapid-autopsy tumor biopsies.

Xiaomeng Huang, Yi Qiao, Samuel W Brady, Rachel E Factor, Erinn Downs-Kelly, Andrew Farrell, Jasmine A McQuerry, Gajendra Shrestha, David Jenkins, W Evan Johnson and 3 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Xiaomeng Huang *Utah Center for Genetic Discovery, University of Utah, Salt Lake City, USA.
Yi Qiao *Utah Center for Genetic Discovery, University of Utah, Salt Lake City, USA.
Samuel W BradyDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, USA.
Rachel E FactorDepartment of Pathology, School of Medicine, University of Utah, Salt Lake City, USA.
Erinn Downs-KellyDepartment of Pathology, School of Medicine, University of Utah, Salt Lake City, USA.
Andrew FarrellUtah Center for Genetic Discovery, University of Utah, Salt Lake City, USA.
Jasmine A McQuerryDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, USA.
Gajendra ShresthaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, USA.
David JenkinsComputational Biomedicine, Department of Medicine, Boston University, Boston, USA.
W Evan JohnsonComputational Biomedicine, Department of Medicine, Boston University, Boston, USA.
Adam L CohenDepartment of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.
Andrea H BildDepartment of Medical Oncology & Therapeutics Research, City of Hope, Duarte, USA.
Gabor T MarthUtah Center for Genetic Discovery, University of Utah, Salt Lake City, USA. gabor.marth@gmail.com.ORCID 0000-0003-0222-1694
University of Utah · USBoston University · USCity of Hope · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
UNIVERSITY OF UTAH MEDICAL INFORMATICS TRAININGT15LM007124 · NLM · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Karen Louise Eilbeck · 1997 to 2026
$22.0M
Project 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI BILD, ANDREA HOPE · 2017 to 2021
$10.5M
Monitoring tumor subclonal heterogeneity over time and spaceU24CA209999 · NCI · UNIVERSITY OF UTAH · PI MARTH, GABOR T, QUINLAN, AARON R · 2016 to 2020
$3.9M
From genomics to natural language processing: A protected environment for research computing in the health scienceS10OD021644 · OD · UNIVERSITY OF UTAH · PI CHEATHAM, THOMAS E. · 2017 to 2017
$494k
NCI NIH HHS P30 CA042014NCI NIH HHS U24 CA209999NCI NIH HHS U54 CA209978NIH HHS S10 OD021644NLM NIH HHS T15 LM007124
6 · The paper itself

Abstract

backgroundMetastatic breast cancer is a deadly disease with a low 5-year survival rate. Tracking metastatic spread in living patients is difficult and thus poorly understood.

methodsVia rapid autopsy, we have collected 30 tumor samples over 3 timepoints and across 8 organs from a triple-negative metastatic breast cancer patient. The large number of sites sampled, together with deep whole-genome sequencing and advanced computational analysis, allowed us to comprehensively reconstruct the tumor's evolution at subclonal resolution.

resultsThe most unique, previously unreported aspect of the tumor's evolution that we observed in this patient was the presence of "subclone incubators," defined as metastatic sites where substantial tumor evolution occurs before colonization of additional sites and organs by subclones that initially evolved at the incubator site. Overall, we identified four discrete waves of metastatic expansions, each of which resulted in a number of new, genetically similar metastasis sites that also enriched for particular organs (e.g., abdominal vs bone and brain). The lung played a critical role in facilitating metastatic spread in this patient: the lung was the first site of metastatic escape from the primary breast lesion, subclones at this site were likely the source of all four subsequent metastatic waves, and multiple sites in the lung acted as subclone incubators. Finally, functional annotation revealed that many known drivers or metastasis-promoting tumor mutations in this patient were shared by some, but not all metastatic sites, highlighting the need for more comprehensive surveys of a patient's metastases for effective clinical intervention.

conclusionsOur analysis revealed the presence of substantial tumor evolution at metastatic incubator sites in a patient, with potentially important clinical implications. Our study demonstrated that sampling of a large number of metastatic sites affords unprecedented detail for studying metastatic evolution.

Indexed as

AutopsyNeoplasm MetastasisBiopsyBreast NeoplasmsEvolution, MolecularFemaleHumansMiddle AgedMutationPhylogenyMetastatic breast cancerSubcloneTumor evolution

Identifiers

PMID34711268
PMCPMC8555066
OpenAlexW3208958338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.